Cargando…

“You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic

BACKGROUND: Opioid agonist treatment (OAT) improves multiple health and social outcomes, yet requirements to attend for supervised dosing can be burdensome and stigmatising. The COVID-19 pandemic and associated restrictions threatened continuity of care and the wellbeing of people receiving OAT, ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Conway, Anna, Treloar, Carla, Crawford, Sione, Degenhardt, Louisa, Dore, Gregory J, Farrell, Michael, Hayllar, Jeremy, Grebely, Jason, Marshall, Alison D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986137/
https://www.ncbi.nlm.nih.gov/pubmed/36907071
http://dx.doi.org/10.1016/j.drugpo.2023.103998
_version_ 1784901104415277056
author Conway, Anna
Treloar, Carla
Crawford, Sione
Degenhardt, Louisa
Dore, Gregory J
Farrell, Michael
Hayllar, Jeremy
Grebely, Jason
Marshall, Alison D.
author_facet Conway, Anna
Treloar, Carla
Crawford, Sione
Degenhardt, Louisa
Dore, Gregory J
Farrell, Michael
Hayllar, Jeremy
Grebely, Jason
Marshall, Alison D.
author_sort Conway, Anna
collection PubMed
description BACKGROUND: Opioid agonist treatment (OAT) improves multiple health and social outcomes, yet requirements to attend for supervised dosing can be burdensome and stigmatising. The COVID-19 pandemic and associated restrictions threatened continuity of care and the wellbeing of people receiving OAT, risking a parallel health crisis. This study sought to understand how adaptations in the complex system of OAT provision impacted and responded to risk environments of people receiving OAT during the COVID-19 pandemic. METHODS: The analysis draws on semi-structured interviews with 40 people receiving and 29 people providing OAT located across Australia. The study considered the risk environments that produce COVID-19 transmission, treatment (non-)adherence, and adverse events for people receiving OAT. Drawing on theories of risk environments and complex adaptive systems, data were coded and analysed to understand how adaptations to the typically rigid system of OAT provision impacted and responded to risk environments during the COVID-19 pandemic. RESULTS: During COVID-19, the complex system of OAT provision demonstrated possibilities for responsive adaptation to the entangled features of risk environments of people receiving OAT. Structural stigma was evident in the services which stayed rigid during the pandemic, requiring people to attend for daily supervised dosing and risking fracturing therapeutic relationships. In parallel, there were several examples of services developing enabling environments by offering flexible care through increased takeaways, treatment subsidies, and home delivery. CONCLUSIONS: Rigidity in the delivery of OAT has been an impediment to achieving health and wellbeing over past decades. To sustain health-promoting environments for people receiving OAT, the wider impacts of the complex system should be acknowledged beyond narrowly defined outcomes relating solely to the medication. Centring people receiving OAT in their own care plans will ensure adaptations in the complex system of OAT provision are responsive to the individual's risk environment.
format Online
Article
Text
id pubmed-9986137
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-99861372023-03-06 “You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic Conway, Anna Treloar, Carla Crawford, Sione Degenhardt, Louisa Dore, Gregory J Farrell, Michael Hayllar, Jeremy Grebely, Jason Marshall, Alison D. Int J Drug Policy Research Paper BACKGROUND: Opioid agonist treatment (OAT) improves multiple health and social outcomes, yet requirements to attend for supervised dosing can be burdensome and stigmatising. The COVID-19 pandemic and associated restrictions threatened continuity of care and the wellbeing of people receiving OAT, risking a parallel health crisis. This study sought to understand how adaptations in the complex system of OAT provision impacted and responded to risk environments of people receiving OAT during the COVID-19 pandemic. METHODS: The analysis draws on semi-structured interviews with 40 people receiving and 29 people providing OAT located across Australia. The study considered the risk environments that produce COVID-19 transmission, treatment (non-)adherence, and adverse events for people receiving OAT. Drawing on theories of risk environments and complex adaptive systems, data were coded and analysed to understand how adaptations to the typically rigid system of OAT provision impacted and responded to risk environments during the COVID-19 pandemic. RESULTS: During COVID-19, the complex system of OAT provision demonstrated possibilities for responsive adaptation to the entangled features of risk environments of people receiving OAT. Structural stigma was evident in the services which stayed rigid during the pandemic, requiring people to attend for daily supervised dosing and risking fracturing therapeutic relationships. In parallel, there were several examples of services developing enabling environments by offering flexible care through increased takeaways, treatment subsidies, and home delivery. CONCLUSIONS: Rigidity in the delivery of OAT has been an impediment to achieving health and wellbeing over past decades. To sustain health-promoting environments for people receiving OAT, the wider impacts of the complex system should be acknowledged beyond narrowly defined outcomes relating solely to the medication. Centring people receiving OAT in their own care plans will ensure adaptations in the complex system of OAT provision are responsive to the individual's risk environment. The Authors. Published by Elsevier B.V. 2023-04 2023-03-06 /pmc/articles/PMC9986137/ /pubmed/36907071 http://dx.doi.org/10.1016/j.drugpo.2023.103998 Text en © 2023 The Authors. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Research Paper
Conway, Anna
Treloar, Carla
Crawford, Sione
Degenhardt, Louisa
Dore, Gregory J
Farrell, Michael
Hayllar, Jeremy
Grebely, Jason
Marshall, Alison D.
“You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic
title “You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic
title_full “You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic
title_fullStr “You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic
title_full_unstemmed “You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic
title_short “You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic
title_sort “you'll come in and dose even in a global pandemic”: a qualitative study of adaptive opioid agonist treatment provision during the covid-19 pandemic
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986137/
https://www.ncbi.nlm.nih.gov/pubmed/36907071
http://dx.doi.org/10.1016/j.drugpo.2023.103998
work_keys_str_mv AT conwayanna youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic
AT treloarcarla youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic
AT crawfordsione youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic
AT degenhardtlouisa youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic
AT doregregoryj youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic
AT farrellmichael youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic
AT hayllarjeremy youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic
AT grebelyjason youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic
AT marshallalisond youllcomeinanddoseeveninaglobalpandemicaqualitativestudyofadaptiveopioidagonisttreatmentprovisionduringthecovid19pandemic